The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival.
 
David M. Peereboom
Consulting or Advisory Role - Abbvie
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Neonc Technologies (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
 
Louis B. Nabors
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Merck/Schering Plough
Travel, Accommodations, Expenses - Merck/Schering Plough
 
Priya Kumthekar
No Relationships to Disclose
 
Michael A. Badruddoja
No Relationships to Disclose
 
Karen L. Fink
Research Funding - CANTEX Pharmaceuticals (Inst); Celldex (Inst); Diffusion Pharmaceuticals (Inst); DNATrix (Inst); Genentech/Roche (Inst); ImmunoCellular Therapeutics (Inst); ImmunoCellular Therapeutics (Inst); Lilly (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Orbus Therapeutics (Inst); Stemline Therapeutics (Inst); Tocagen (Inst); Vascular Biogenics (Inst)
 
Frank S. Lieberman
No Relationships to Disclose
 
Surasak Phuphanich
No Relationships to Disclose
 
Erin M. Dunbar
No Relationships to Disclose
 
Tobias Walbert
No Relationships to Disclose
 
David Schiff
No Relationships to Disclose
 
David Dinh Tran
No Relationships to Disclose
 
Lynn Stuart Ashby
Honoraria - Arbor Pharmaceuticals
 
Nicholas A. Butowski
Consulting or Advisory Role - Abbvie; Genentech/Roche; Medicenna; Omniox
Speakers' Bureau - Genentech/Roche
Research Funding - Abbvie; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; Medicenna; Merck; Merrimack; Tocagen
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Merck; Novocure; Regeneron
Speakers' Bureau - Prime Oncology
 
Ross Lindsay
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Stemline Therapeutics
Travel, Accommodations, Expenses - Stemline Therapeutics
 
John Bullington
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Stemline Therapeutics
Travel, Accommodations, Expenses - Stemline Therapeutics
 
Michael Schulder
No Relationships to Disclose
 
Jonathan Sherman
No Relationships to Disclose
 
Trishna Goswami
Employment - Stemline Therapeutics
Stock and Other Ownership Interests - Stemline Therapeutics
Travel, Accommodations, Expenses - Stemline Therapeutics
 
David A. Reardon
Honoraria - Abbvie; Bristol-Myers Squibb; Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Midatech Pharma (Inst); Tragara (Inst)